3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Ritodrine.
Acebutolol
The risk or severity of adverse effects can be increased when Ritodrine is combined with Acebutolol.
Alfuzosin
Alfuzosin may decrease the vasoconstricting activities of Ritodrine.
Advertisement
Alprenolol
Alprenolol may decrease the bronchodilatory activities of Ritodrine.
Amineptin
The risk or severity of adverse effects can be increased when Amineptine is combined with Ritodrine.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ritodrine.
Advertisement
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Ritodrine.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Ritodrine.
Atenolol
Atenolol may decrease the bronchodilatory activities of Ritodrine.
Advertisement
Atomoxetine
Atomoxetine may increase the hypertensive activities of Ritodrine.
Atosiban
The risk or severity of adverse effects can be increased when Ritodrine is combined with Atosiban.
Azosemide
Ritodrine may increase the hypokalemic activities of Azosemide.
Bendroflumethiazide
Ritodrine may increase the hypokalemic activities of Bendroflumethiazide.
Benzphetamine
The risk or severity of adverse effects can be increased when Benzphetamine is combined with Ritodrine.
Benzylpenicilloyl polylysine
Ritodrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BETAHISTINE
The therapeutic efficacy of Ritodrine can be decreased when used in combination with Betahistine.
Betaxolol
Betaxolol may decrease the bronchodilatory activities of Ritodrine.
Bisoprolol
Bisoprolol may decrease the bronchodilatory activities of Ritodrine.
Bopindolol
Bopindolol may decrease the bronchodilatory activities of Ritodrine.
Bromocriptine
Bromocriptine may increase the hypertensive and vasoconstricting activities of Ritodrine.
Bumetanide
Ritodrine may increase the hypokalemic activities of Bumetanide.
Bunazosin
Bunazosin may decrease the vasoconstricting activities of Ritodrine.
Bupranolol
Bupranolol may decrease the bronchodilatory activities of Ritodrine.
Cabergoline
Cabergoline may increase the hypertensive and vasoconstricting activities of Ritodrine.
Carteolol
Carteolol may decrease the bronchodilatory activities of Ritodrine.
Carvedilol
Carvedilol may decrease the vasoconstricting activities of Ritodrine.
Celiprolol
The risk or severity of adverse effects can be increased when Ritodrine is combined with Celiprolol.
Chlorothiazide
Ritodrine may increase the hypokalemic activities of Chlorothiazide.
Chlorthalidone
Ritodrine may increase the hypokalemic activities of Chlorthalidone.
Clenbuterol
The risk or severity of adverse effects can be increased when Ritodrine is combined with Clenbuterol.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Ritodrine.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritodrine.
Cyclopenthiazide
Ritodrine may increase the hypokalemic activities of Cyclopenthiazide.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Ritodrine.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Ritodrine.
Dihydroergotamine
Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Ritodrine.
Dobutamine
The risk or severity of adverse effects can be increased when Dobutamine is combined with Ritodrine.
Dopamine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Dopamine.
Dothiepin
The risk or severity of adverse effects can be increased when Dosulepin is combined with Ritodrine.
Doxazosin
Doxazosin may decrease the vasoconstricting activities of Ritodrine.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Ritodrine.
Duloxetine
Duloxetine may increase the tachycardic activities of Ritodrine.
Ephedrine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Ephedrine.
Epinephrine
The risk or severity of adverse effects can be increased when Epinephrine is combined with Ritodrine.
ergoloid mesylates, USP
Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Ritodrine.
Ergonovine
Ergonovine may increase the hypertensive and vasoconstricting activities of Ritodrine.
Ergotamine
Ergotamine may increase the hypertensive and vasoconstricting activities of Ritodrine.
Esmolol
Esmolol may decrease the bronchodilatory activities of Ritodrine.
Ethacrynate
Ritodrine may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Ritodrine may increase the hypokalemic activities of Etacrynic acid.
Etilefrine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Etilefrine.
Fenoterol
The risk or severity of adverse effects can be increased when Ritodrine is combined with Fenoterol.
Furazolidone
The risk or severity of adverse effects can be increased when Furazolidone is combined with Ritodrine.
Furosemide
Ritodrine may increase the hypokalemic activities of Furosemide.
Hydrochlorothiazide
Ritodrine may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Ritodrine may increase the hypokalemic activities of Hydroflumethiazide.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Ritodrine.
Indapamide
Ritodrine may increase the hypokalemic activities of Indapamide.
Indoramin
Indoramin may decrease the vasoconstricting activities of Ritodrine.
Iproniazid
The risk or severity of adverse effects can be increased when Iproniazid is combined with Ritodrine.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ritodrine.
Isoproterenol
The risk or severity of adverse effects can be increased when Ritodrine is combined with Isoprenaline.
Isoxsuprine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Isoxsuprine.
Labetalol
The risk or severity of adverse effects can be increased when Labetalol is combined with Ritodrine.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Ritodrine.
Linezolid
Linezolid may increase the hypertensive activities of Ritodrine.
Mephentermine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Mephentermine.
Metaproterenol
The risk or severity of adverse effects can be increased when Orciprenaline is combined with Ritodrine.
Metaraminol
The risk or severity of adverse effects can be increased when Metaraminol is combined with Ritodrine.
Methamphetamine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Methamphetamine.
Methoxamine
The risk or severity of adverse effects can be increased when Methoxamine is combined with Ritodrine.
Methyclothiazide
Ritodrine may increase the hypokalemic activities of Methyclothiazide.
Methylene blue
The risk or severity of adverse effects can be increased when Methylene blue is combined with Ritodrine.
Methylergonovine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Ritodrine.
Metolazone
Ritodrine may increase the hypokalemic activities of Metolazone.
Metoprolol
Metoprolol may decrease the bronchodilatory activities of Ritodrine.
Midodrine
The risk or severity of adverse effects can be increased when Midodrine is combined with Ritodrine.
Milnacipran
Milnacipran may increase the tachycardic activities of Ritodrine.
Minaprine
The risk or severity of adverse effects can be increased when Minaprine is combined with Ritodrine.
Mirtazapine
The risk or severity of adverse effects can be increased when Mirtazapine is combined with Ritodrine.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Ritodrine.
Nabilone
Nabilone may increase the tachycardic activities of Ritodrine.
Nebivolol
Nebivolol may decrease the bronchodilatory activities of Ritodrine.
Nialamide
The risk or severity of adverse effects can be increased when Nialamide is combined with Ritodrine.
Norepinephrine
The risk or severity of adverse effects can be increased when Norepinephrine is combined with Ritodrine.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ritodrine.
Nylidrin
The risk or severity of adverse effects can be increased when Ritodrine is combined with Nylidrin.
Opipramol
The risk or severity of adverse effects can be increased when Opipramol is combined with Ritodrine.
Oxprenolol
Oxprenolol may decrease the bronchodilatory activities of Ritodrine.
Oxymetazoline
The risk or severity of adverse effects can be increased when Ritodrine is combined with Oxymetazoline.
p-Hydroxyamphetamine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Hydroxyamphetamine.
Pargyline
The risk or severity of adverse effects can be increased when Pargyline is combined with Ritodrine.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Ritodrine.
Phenmetrazine
The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Ritodrine.
Phentermine
The risk or severity of adverse effects can be increased when Phentermine is combined with Ritodrine.
PHENTERMINE RESIN
The risk or severity of adverse effects can be increased when Phentermine is combined with Ritodrine.
Phenylephrine
The risk or severity of adverse effects can be increased when Phenylephrine is combined with Ritodrine.
Phenylpropanolamine
The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Ritodrine.
Piretanide
Ritodrine may increase the hypokalemic activities of Piretanide.
Polythiazide
Ritodrine may increase the hypokalemic activities of Polythiazide.
Prazosin
Prazosin may decrease the vasoconstricting activities of Ritodrine.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Ritodrine.
Procaterol
The risk or severity of adverse effects can be increased when Ritodrine is combined with Procaterol.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Ritodrine.
Pseudoephedrine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Pseudoephedrine.
Quinethazone
Ritodrine may increase the hypokalemic activities of Quinethazone.
Racepinephrine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Racepinephrine.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Ritodrine.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Ritodrine.
Silodosin
Silodosin may decrease the vasoconstricting activities of Ritodrine.
Spironolactone
Spironolactone may decrease the vasoconstricting activities of Ritodrine.
Synephrine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Synephrine.
Tamsulosin
Tamsulosin may decrease the vasoconstricting activities of Ritodrine.
Tedizolid
Tedizolid Phosphate may increase the hypertensive activities of Ritodrine.
Tedizolid Phosphate
Tedizolid Phosphate may increase the hypertensive activities of Ritodrine.
Terazosin
Terazosin may decrease the vasoconstricting activities of Ritodrine.
Terbutaline
The risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline.
Terbutaline Sulfate
The risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline.
Tetrahydrocannabinol
Dronabinol may increase the tachycardic activities of Ritodrine.
Tetrahydrozoline
The risk or severity of adverse effects can be increased when Ritodrine is combined with Tetryzoline.
Tianeptine
The risk or severity of adverse effects can be increased when Tianeptine is combined with Ritodrine.
Timolol
Timolol may decrease the bronchodilatory activities of Ritodrine.
Timolol Anhydrous
Timolol may decrease the bronchodilatory activities of Ritodrine.
Toloxatone
The risk or severity of adverse effects can be increased when Toloxatone is combined with Ritodrine.
Torsemide
Ritodrine may increase the hypokalemic activities of Torasemide.
Tramazoline
The risk or severity of adverse effects can be increased when Ritodrine is combined with Tramazoline.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritodrine.
Trichlormethiazide
Ritodrine may increase the hypokalemic activities of Trichlormethiazide.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Ritodrine.
Tyramine
The risk or severity of adverse effects can be increased when Ritodrine is combined with Tyramine.
Urapidil
Urapidil may decrease the vasoconstricting activities of Ritodrine.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ritodrine.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Ritodrine.
